Invirsa Inc.
Columbus, US · Founded 2016 · Delaware corporation · 5 known investors
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical Devices
Founders & leadership
Invirsa Inc. was founded in 2016 by Robert Shalwitz.
RS
Robert ShalwitzFounder
RW
Rachael WingoExecutive
Board
WE
TW
Tim WillisBoard director
FV
BG
MV
Investors · 5
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 4 rounds · 2020–2025
▶$2.9MraisedAug 2025 · 14 investors · PharmaceuticalsRule 506(b)
▶$2.9MraisedAug 2025 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rachael WingoExecutive Officer
- Wayne EmbreeDirector
- Tim WillisDirector
- Robert ShalwitzExecutive Officer, Director
- Faith VoinovichDirector
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1000KraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$1000KraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wayne EmbreeDirector
- Samuel LeeDirector
- Tim WillisDirector
- Faith VoinovichDirector
- Robert ShalwitzExecutive Officer, Director
- Offering amount
- $1000K
- Amount sold
- $1000K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedDec 2022 · 8 investors · PharmaceuticalsRule 506(b)
▶$6MraisedDec 2022 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert ShalwitzExecutive Officer, Director
- Faith VoinovichDirector
- Wayne EmbreeDirector
- Samuel LeeDirector
- Tim WillisDirector
- Offering amount
- $7.7M
- Amount sold
- $6M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.2KraisedDec 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$40.2KraisedDec 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Faith VoinovichDirector
- Bethany GeorgeDirector
- Michael VenerableDirector
- Robert ShalwitzExecutive Officer, Director
- Tim WillisDirector
- Offering amount
- $40.2K
- Amount sold
- $40.2K
- Minimum investment
- $40.2K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Invirsa Inc. do?
- Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
- Who founded Invirsa Inc.?
- Invirsa Inc. was founded by Robert Shalwitz in 2016.
- Who are Invirsa Inc.'s investors?
- Invirsa Inc.'s investors include CincyTech, JobsOhio Ventures, Jumpstart Ventures, Ohio Innovation Fund, Rev1 Ventures.
- How much funding has Invirsa Inc. raised?
- Invirsa Inc. has disclosed $9.9M raised across 4 rounds.
- Where is Invirsa Inc. headquartered?
- Invirsa Inc. is headquartered in Columbus, US.